Lawmakers on the U.S. Senate Judiciary Committee urged the Trump administration to conduct a scientific review of a Justice Department-backed bill to classify all illicit chemical knockoffs of the potent painkiller fentanyl in the same legal category as heroin.
Prices, profits and promotional spend are closely linked. Reduce prices and promotion will plummet. But wait, the Republicans are in control. Accordingly, pharma, its marketing partners and even Wall Street often rest easy, especially when Republicans control Congress and the White House.
The Trump administration scrapped a proposal for lowering prescription medicine prices, backing down from a policy that would have required health insurers to pass on billions of dollars in rebates they receive from drugmakers to Medicare patients.
The Trump administration plans to change the way it pays for kidney disease treatments to favor lower cost care at home and transplants over the current standard, dialysis clinics, top health officials said during a press briefing.
A federal appeals court panel expressed skepticism to Democratic calls to overturn the ruling of a Texas judge who found the landmark U.S. healthcare reform law unconstitutional.
The United States pays more per capita for prescription drugs than any other country in the world, which is a huge concern for patients and insurance providers.
U.S. President Donald Trump plans to issue an executive order asking health insurers and doctors to disclose new details about healthcare costs in an attempt to improve price transparency, the Wall Street Journal reported, citing people familiar with the matter.
As concerns over the price of prescription medicine continue to make headlines as the country barrels toward another election, a new study from the Scripps Research bolsters an argument touted by the pharmaceutical industry over the rebate system.
The House Appropriations Committee proposed a 2020 draft fiscal year funding bill. The FDA would receive a 6 percent increase in discretionary funding over 2019, amounting to a $184 million bump.
U.S. states filed a lawsuit accusing Teva Pharmaceuticals USA Inc. of orchestrating a sweeping scheme with 19 other drug companies to inflate drug prices – sometimes by more than 1,000 percent – and stifle competition for generic drugs, state prosecutors said.
U.S. President Donald Trump slammed the pharmaceutical industry for high prices of prescription drugs and vowed to allow U.S. states to buy medicines from other countries if they cost less.